Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

78.60 -8.57 (-9.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
20 21 Next >
News headline image
Cancer Test Firm Guardant Health Posts Smaller Than Expected Q3 Loss, Lifts Annual Sales Outlook ↗
Guardant Health Inc (NASDAQ: GH) reported Q3 revenue of $143 million, up 22% Y/Y, beating the consensus of $137.37 million 
Via Benzinga
News headline image
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
News headline image
Guardant Health to Participate in Upcoming November Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
From Guardant Health, Inc.
Via Business Wire
News headline image
The Latest Analyst Ratings for Guardant Health ↗
 
Via Benzinga
News headline image
Why Guardant Health Stock Popped Again Today ↗
Wall Street loves this unprofitable biotech. 
Via The Motley Fool
News headline image
Analyst Expectations for Guardant Health's Future ↗
 
Via Benzinga
News headline image
Bull Of The Day: NeoGenomics ↗
NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. 
Via Talk Markets
News headline image
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
The Latest Analyst Ratings for Guardant Health ↗
 
Via Benzinga
News headline image
Preview: Guardant Health's Earnings ↗
 
Via Benzinga
News headline image
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
From Guardant Health, Inc.
Via Business Wire
News headline image
1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years ↗
This company's fight against a deadly disease could pay off. 
Via The Motley Fool
News headline image
Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health? ↗
The oncology diagnostic companies are looking for better solutions in early cancer diagnosis. 
Via The Motley Fool
News headline image
Why Guardant Health Stock Jumped 15% This Week ↗
The precision oncology leader benefited from a pair of positive analyst notes this week. Here's what investors need to know. 
Via The Motley Fool
News headline image
Guardant Health Has 'Underlying Business Strength' Says This Bullish Analyst ↗
Shares of Guardant Health Inc (NASDAQ: GH) climbed during the premarket trading session and morning on Wednesday. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 ↗
 
Via Benzinga
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The... 
Via FinancialNewsMedia
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 ↗
 
Via Benzinga
News headline image
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year ↗
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. 
Via Benzinga
News headline image
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Host Investor Day on September 7, 2023
From Guardant Health, Inc.
Via Business Wire
News headline image
2 Cathie Wood Stocks to Buy and Hold for 10 Years ↗
These companies' growth stories still have plenty of exciting chapters ahead. 
Via The Motley Fool
News headline image
Guardant Health Stock Sees Renewed Technical Strength ↗
Guardant Health stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 79 to 85. 
Via Investor's Business Daily
News headline image
Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.